Genmab reports Arzerra data

Genmab A/S (CSE:GEN) said top-line data from an open-label Phase II trial in 58 previously untreated patients with follicular non-Hodgkin's lymphoma (NHL) showed that 500 and 1,000 mg Arzerra in combination with CHOP chemotherapy led to overall response rates (ORR) of 90% and 100%, respectively. Additionally, the low and high doses of Arzerra led to complete remission rates of 24% and 38%, respectively. The company did not return calls to clarify a time point for response or remission rates. Last week, Genmab said top-line data from a Phase III trial of the human mAb against CD20 to treat refractory follicular NHL did not reach a level that would trigger a milestone payment from partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) (See BioCentury, Aug. 24, 2009). ...